A Flagship VentureLabs Company

T2 Biosystems, Inc.

101 Hartwell Avenue

Lexington, MA  02421

Tel: 781.457.1200


Leadership:
John McDonough
CEO


Website:
www.t2biosystems.com


Information:
info@t2biosystems.com

T2 Biosystems, Inc.

Flagship Partners:  Harry Wilcox
Initial Investment: 
2006
Status: 
Private

T2 Biosystems is setting a new standard in clinical diagnostics powered by T2MR, the world’s first direct detection technology that is designed to deliver superior sensitivity at unmatched speed to guide more effective clinical decision-making. T2 Bio’s pipeline of molecular diagnostic and hemostasis products is focused on conditions where rapid and accurate results will have the greatest impact on patients’ lives and healthcare costs. The Company’s lead products, T2Candida and T2Bacteria, are designed to identify life-threatening pathogens associated with sepsis directly from whole blood, potentially up to 25-times faster than blood culture.

Harry Wilcox serves on the Board of Directors.